Table 1 Summary of Baseline Patient Characteristics - Matched HAQ Cohort
Variable Statistic or Category | All HCQ Users with more than one HAQ (n = 50) | All non-HCQ Users with more than one HAQ (n = 150) | P Value |
|---|---|---|---|
Age (at IC) | . | ||
N | 50 | 150 | 0.954 |
Mean (SD) | 49.836 (12.1293) | 49.970 (14.9121) | . |
Median (Min, Max) | 51.662 (18.23, 68.83) | 50.560 (13.21, 81.75) | . |
. | |||
Sex | . | ||
Female | 46 (92.0%) | 128 (85.3%) | 0.225 |
Male | 4 (8.0%) | 22 (14.7%) | . |
Duration since first non-Raynauds (years) | . | ||
N | 50 | 150 | 0.608 |
Mean (SD) | 8.233 (9.1558) | 9.091 (10.5793) | . |
Median (Min, Max) | 4.961 (0.16, 45.17) | 4.812 (0.00, 62.29) | . |
. | |||
White race | 45 (90.0%) | 140 (93.3%) | . |
Diffuse/Limited | . | ||
Diffuse cutaneous SSc | 17 (36.2%) | 52 (35.4%) | 0.108 |
Limited cutaneous SSc | 26 (55.3%) | 92 (62.6%) | . |
Unknown | 4 (8.5%) | 3 (2.0%) | . |
Missing | 3 | 3 | . |
Baseline HAQ-DI | . | ||
N | 50 | 139 | 0.515 |
Mean (SD) | 0.865 (0.6822) | 0.783 (0.7926) | . |
Median (Min, Max) | 0.938 (0.00, 2.75) | 0.500 (0.00, 2.88) | . |
. | |||
Baseline Global VAS | . | ||
N | 47 | 114 | 0.767 |
Mean (SD) | 39.6 (26.59) | 38.2 (27.69) | . |
Median (Min, Max) | 38.0 (1, 99) | 32.5 (0, 99) | . |
. | |||
Number of HAQ-DI visits | . | ||
N | 50 | 150 | 0.313 |
Mean (SD) | 3.0 (1.48) | 3.3 (1.60) | . |
Median (Min, Max) | 2.5 (2, 10) | 3.0 (2, 11) | . |
. | |||
Corticosteroid Use | 21 (42.0%) | 61 (40.7%) | 0.868 |
Immunosuppresive Use | 6 (12.0%) | 17 (11.3%) | 0.898 |
DMARD Use | 5 (10.0%) | 14 (9.3%) | 0.889 |
Vasoactive Use | 34 (68.0%) | 110 (73.3%) | 0.467 |